Brokerages predict that AngioDynamics, Inc. (NASDAQ:ANGO) will post $92.85 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for AngioDynamics’ earnings. The lowest sales estimate is $92.80 million and the highest is $92.90 million. AngioDynamics reported sales of $88.32 million during the same quarter last year, which would suggest a positive year over year growth rate of 5.1%. The business is expected to issue its next earnings report before the market opens on Wednesday, July 10th.
On average, analysts expect that AngioDynamics will report full year sales of $356.05 million for the current year, with estimates ranging from $356.00 million to $356.09 million. For the next fiscal year, analysts anticipate that the company will post sales of $283.18 million, with estimates ranging from $283.16 million to $283.20 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, April 2nd. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.03). AngioDynamics had a return on equity of 5.41% and a net margin of 1.30%. The firm had revenue of $86.34 million during the quarter, compared to the consensus estimate of $88.30 million. During the same quarter in the previous year, the company earned $0.23 EPS. The business’s revenue was up 3.0% compared to the same quarter last year.
NASDAQ ANGO opened at $19.69 on Friday. AngioDynamics has a 1 year low of $18.11 and a 1 year high of $25.48. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.70 and a current ratio of 2.68. The company has a market cap of $732.78 million, a price-to-earnings ratio of 26.61 and a beta of 0.71. The business has a fifty day moving average price of $19.40.
Large investors have recently modified their holdings of the stock. Penn Capital Management Co. Inc. purchased a new position in shares of AngioDynamics in the 4th quarter worth about $2,057,000. Metropolitan Life Insurance Co. NY boosted its holdings in shares of AngioDynamics by 417.0% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,559 shares of the medical instruments supplier’s stock worth $253,000 after buying an additional 10,130 shares during the last quarter. South Dakota Investment Council boosted its holdings in shares of AngioDynamics by 53.4% in the 1st quarter. South Dakota Investment Council now owns 15,800 shares of the medical instruments supplier’s stock worth $361,000 after buying an additional 5,500 shares during the last quarter. Tibra Equities Europe Ltd purchased a new position in shares of AngioDynamics in the 1st quarter worth about $245,000. Finally, Segall Bryant & Hamill LLC boosted its holdings in shares of AngioDynamics by 19.2% in the 4th quarter. Segall Bryant & Hamill LLC now owns 1,136,657 shares of the medical instruments supplier’s stock worth $22,881,000 after buying an additional 183,368 shares during the last quarter. 98.46% of the stock is currently owned by institutional investors.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Featured Story: What is a good rate of return for a mutual fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.